Recent Advances in Understanding the
Pathogenesis of Atopic Dermatitis

New Horizons in the Treatment and Management of Atopic Dermatitis is a 4-part
series that will provide attendees with the latest information in Atopic Dermatitis.

This is Part 3 of the series focusing on New Horizons in the
Treatment and Management of Atopic Dermatitis

This activity is an archive from the webinar held March 8, 2017. If you participated
in the March 8 webinar, you are not eligible for credits from this activity.

This activity is valid from April 15, 2017 to April 30, 2019

Instructions for CME/CNE: Listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by an educational grant from
Sanofi Genzyme and Regeneron Pharmaceuticals

Description:
Atopic dermatitis is a common chronic inflammatory skin disease characterized by persistent itching that can severely affect quality of life. This condition evolves from a combination of skin barrier defects and immune-mediated responses involving activated T-helper cells and related cytokines. Our improved understanding of the pathophysiology underlying atopic dermatitis is resulting in the development of targeted therapies for children and adult patients with this disease. There are approximately 17.8 million people with moderate to severe eczema or atopic dermatitis in the United States. This session will address the role of emerging therapies and their pathophysiologic mechanisms that block IL-4/IL-13 pathways.

Upon Completion of this activity, participants will be able to:

  • Define the research underlying the most current understanding of the pathophysiologic mechanisms of atopic dermatitis

  • Identify the latest research regarding the development of therapeutic agents that address the pathophysiologic mechanisms of atopic dermatitis

  • Discuss the role of emerging therapies that block the IL-4/IL-13 signaling pathway, and how they might be integrated into the evolving treatment paradigm
     

Faculty: Lawrence F. Eichenfield, MD
Professor of Dermatology and Pediatrics
Chief, Pediatric and Adolescent Dermatology
University of California, San Diego

Disclosure:

Dr. Eichenfield receives honoraria for consultant, advisory board or speaker engagement from Anacor, Celgene, Genentech, Otsuka, Regeneron and Valeant. He is compensated with equity options for consulting with TopMD. He serves as an investigator with no compensation for Astellas Pharma US and Regeneron. His presentation has been peer reviewed.
 
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The National Association of Managed Care Physicians designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity will receive up to 1 credit in continuing nursing education.

The American Board of Managed Care Nurses has approved this activity for a maximum of 1 contact hour towards CMCN recertification.

This educational activity is supported by an educational grant from
Sanofi Genzyme and Regeneron Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue